Clinical Outcomes of Covid-19 in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study

Lauranne A. A. P. Derikx*, Marten A. Lantinga, Dirk J. de Jong, Willemijn A. van Dop, Rob H. Creemers, Tessa E. H. Römkens, Jeroen M. Jansen, Nofel Mahmmod, Rachel L. West, Adriaan C. I. T. L. Tan, Alexander G. L. Bodelier, Moniek H. P. Gorter, Paul J. Boekema, Eric R. C. Halet, Carmen S. Horjus, Maarten A. van Dijk, Meike M. C. Hirdes, Ludger S. M. Epping Stippel, Bindia Jharap, Maurice W. M. D. LutgensMaurice G. Russel, Lennard P. L. Gilissen, Sjoukje Nauta, Adriaan A. van Bodegraven, Frank Hoentjen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background and Aims: The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical presentation, disease course, and outcomes of COVID-19 in IBD patients. Second, we determined COVID-19 incidences in IBD patients and compared this with the general population. Methods: We conducted a multicentre, nationwide IBD cohort study in The Netherlands and identified patients with COVID-19. First, we assessed the COVID-19 disease course and outcomes. Second, we compared COVID-19 incidences between our IBD study cohort and the general Dutch population. Results: We established an IBD cohort of 34 763 patients. COVID-19 was diagnosed in 100/34 763 patients [0.29%]; 20/100 of these patients [20%] had severe COVID-19 defined as admission to the intensive care unit, mechanical ventilation, and/or death. Hospitalisation occurred in 59/100 [59.0%] patients and 13/100 [13.0%] died. All patients who died had comorbidities and all but one were ≥65 years old. In line, we identified ≥1 comorbidity as an independent risk factor for hospitalisation (odds ratio [OR] 4.20, 95% confidence interval [CI] 1.58-11.17,; p = 0.004). Incidences of COVID-19 between the IBD study cohort and the general population were comparable (287.6 [95% CI 236.6-349.7] versus 333.0 [95% CI 329.3-336.7] per 100000 patients, respectively; p = 0.15). Conclusions: Of 100 cases with IBD and COVID-19, 20% developed severe COVID-19, 59% were hospitalised and 13% died. A comparable COVID-19 risk was found between the IBD cohort [100/34 763 = 0.29%] and the general Dutch population. The presence of ≥1 comorbidities was an independent risk factor for hospitalisation due to COVID-19.
Original languageEnglish
Pages (from-to)529-539
Number of pages11
JournalJournal of Crohn's and Colitis
Volume15
Issue number4
DOIs
Publication statusPublished - 1 Apr 2021

Cite this